The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
about
Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combinationPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyEvolving treatment paradigms for chemotherapy-induced nausea and vomitingDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataEfficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials.The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Evaluating the various phases of cisplatin-induced emesis in rats.Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.Netupitant PET imaging and ADME studies in humans.Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimensComparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomizOpen-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with PalonosetronEfficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chThe comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomitingPalonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisComparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery.Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapyTreatment of Nausea and Vomiting During Chemotherapy.A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.Pathophysiological and neurochemical mechanisms of postoperative nausea and vomitingCurrent pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Measuring the nausea-to-emesis continuum in non-human animals: refocusing on gastrointestinal vagal signalingReview of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew).Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.A randomized, double-blind trial evaluating the efficacy of palonosetron with total intravenous anesthesia using propofol and remifentanil for the prevention of postoperative nausea and vomiting after gynecologic surgery.A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.
P2860
Q26748524-7D2F78EA-9A00-482F-8B3B-D4CF694F6E7AQ26783229-32279078-5D3D-4BB8-AB13-4F7E3D7DD5C8Q27024463-048EDCBB-404C-4D36-A876-4F76FD552815Q28084970-9069A937-B3D5-403B-8BEA-D66E22C6AB83Q33735025-8E78A21A-EF20-4AD2-8BA8-8E38D6B78151Q33805465-EE5781B9-17AB-4CE9-9620-986D312E919FQ34166946-D72709E6-3FE8-443D-905F-3F0E63FED3EAQ34293135-F7E0A112-62B2-4C3E-A5A3-9E54093C92C5Q34348084-619D0591-CC5F-41F2-841C-C2B5E0249456Q34377521-0F19B9CC-BBA8-4832-B67E-BD02028CFAAEQ34582576-BEBE9C97-96D3-4F1F-8EA4-681BC6C08C66Q35028927-49F8514F-014E-4003-B53C-A292233B215BQ35904224-414BB3B8-F432-4FB9-B9AE-B68FAF9118B3Q36004950-C5D3A175-F5F0-4710-BD2A-F1FD9D89D60AQ36354684-2ED9E11D-35EA-4A5F-838A-EC1B947DFA63Q36524349-F5507B0F-FBE3-451C-B261-456F4F0AB549Q36636930-ADE0668D-6FE6-450D-A407-3C656E89C1A1Q37161371-354FA429-448F-4ABA-BBF9-01035BE2D37EQ37503489-71777C81-07BC-4E71-A2CF-9B4F6BC9F51FQ37551843-6F82AA32-FACD-4192-953E-44DD28D3D308Q37559641-F02FA07A-6445-4885-9E3E-417704346A36Q37609798-D772E496-6ABC-4FC5-AF5A-A21EEDD7C8CDQ38132238-5FA340FA-9302-4F0A-B8BE-30B47996CB2AQ38215005-0E597EA6-E5E2-494B-A815-E010782B89B6Q38264147-CEC8811B-BF3D-4F95-9F3C-2F1ED93CD7E1Q38443441-AB6CCE76-CFBF-47EA-B318-BDBBB7C9D712Q38497106-CF302D12-7A87-4A82-AFBD-CDB989FF0CFAQ38571176-66AFB388-4E15-4030-99E4-36760BAC9F5FQ38650400-31410E2D-E48F-4A82-9C0F-AC32D48E31C2Q38676345-F35C8312-02B3-447A-839D-C6EF3D010538Q38980779-985A72A1-6F85-4677-B4F8-8CE91924D83FQ39173196-2B64599A-3414-4B46-9E54-9ACAA8A1F4BCQ39213490-E6A5DE61-1229-44B8-A9E4-E1CACC033A52Q40978787-9F66E959-D3EF-40D5-A439-65A8890E6395Q41385767-96A1A48D-786D-4990-B4FF-45FAB3AF3B0CQ42107538-9197754F-3E46-48CA-B4BD-C496FBF10996Q42201240-EE739EB3-ED5D-4BFB-9F9D-C4BE07BF563BQ43581868-771F0156-C7A7-4E9B-B78E-DEBA169DF2A8Q47386798-095D28D0-ABF9-4FE1-B779-84BF0E2C5D18Q47841681-8AAAE59B-42D1-47DF-939D-474126464C39
P2860
The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@ast
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@en
type
label
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@ast
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@en
prefLabel
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@ast
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@en
P2093
P2860
P356
P1476
The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.
@en
P2093
Ajit G Thomas
Barbara S Slusher
Camilo Rojas
Claudio Pietra
Marigo Stathis
Sergio Cantoreggi
Silvia Sebastiani
P2860
P304
P356
10.1124/JPET.110.166181
P407
P577
2010-08-19T00:00:00Z